Anondita Medicare CWIP reaches Rs 74.21 crore in first half
Key highlights
- Anondita Medicare reported capital work-in-progress of Rs 74.21 crore at September 30, 2026, up from Rs 41.50 crore at March 31, 2026.
- Anondita Medicare used Rs 47.94 crore in investing activities in the half year ended September 30, 2026, versus Rs 9.46 crore a year earlier.
- Anondita Medicare reported Rs 48.01 crore of purchases or advances for property, plant and equipment and intangible assets in the half year.
- Anondita Medicare’s consolidated property, plant and equipment rose to Rs 52.97 crore from Rs 39.10 crore in six months.
powered by IRIS

Anondita Medicare Limited reported consolidated capital work-in-progress of Rs 74.21 crore at September 30, 2026, up Rs 32.71 crore from March 31, 2026, while net cash used in investing activities during the half year was Rs 47.94 crore. The balance-sheet increase indicates a larger reported value of assets still under execution.
Know Anondita Medicare inside out
Results, valuation, peers and who's buying, in one view.
What was Anondita Medicare’s capital work-in-progress at September 2026?
Capital work-in-progress was Rs 74.21 crore at September 30, 2026, compared with Rs 41.50 crore at March 31, 2026 and Rs 15.22 crore at September 30, 2025. The balance increased by Rs 32.71 crore over the six months ended September 30, 2026, and by Rs 58.98 crore from the corresponding reporting date a year earlier.
Anondita Medicare classified the Rs 74.21 crore balance within non-current assets in its unaudited consolidated balance sheet. Property, plant and equipment, a separate non-current asset category, stood at Rs 52.97 crore at September 30, 2026, against Rs 39.10 crore at March 31, 2026. Combined, the two categories totalled Rs 127.18 crore, compared with Rs 80.59 crore six months earlier.
The increase in work-in-progress exceeded the Rs 13.87 crore rise in property, plant and equipment between March and September 2026. The consolidated filing does not identify the projects within capital work-in-progress, their planned commissioning dates, or the intended use of the assets. It therefore records the value of projects under execution without specifying a completion timetable.
How much cash did Anondita Medicare use for investing in the first half?
Anondita Medicare used Rs 47.94 crore in investing activities during the half year ended September 30, 2026, compared with Rs 9.46 crore in the half year ended September 30, 2025. The reported investing outflow increased by Rs 38.48 crore year on year as the capital work-in-progress balance rose.
The consolidated cash-flow statement recorded Rs 48.01 crore of purchases of, or advances for, property, plant and equipment and intangible assets in the September 2026 half year. It also recorded Rs 6.20 lakh of interest received, producing a net investing outflow of Rs 47.94 crore. The asset purchase or advance amount was more than five times the Rs 9.46 crore net investing outflow in the corresponding 2025 half year.
For the year ended March 31, 2026, Anondita Medicare had reported a Rs 62.70 crore net cash outflow from investing activities. The Rs 47.94 crore outflow in the following six months shows that investing cash deployment continued into the September 2026 half year. The filing does not split the Rs 48.01 crore purchase or advance amount among equipment, buildings, land or other asset components.
How did Anondita Medicare’s asset base change by September 2026?
Anondita Medicare’s consolidated total assets reached Rs 351.79 crore at September 30, 2026, from Rs 184.83 crore at March 31, 2026. The Rs 166.96 crore increase included higher capital work-in-progress, property and equipment, inventories, trade receivables, cash and short-term loans and advances.
Inventories increased to Rs 35.17 crore at September 30, 2026 from Rs 20.75 crore at March 31, 2026, while trade receivables rose to Rs 60.02 crore from Rs 51.86 crore. Short-term loans and advances increased to Rs 23.57 crore from Rs 11.15 crore. These reported movements show that the balance-sheet expansion extended beyond assets under execution into working-capital categories.
Cash and cash equivalents were Rs 91.51 crore at September 30, 2026, compared with Rs 9.65 crore at March 31, 2026. The consolidated cash-flow statement recorded a Rs 81.86 crore net increase in cash and cash equivalents for the half year. That increase followed Rs 131.50 crore of net cash from financing activities and the Rs 47.94 crore investing outflow.
Got a follow-up? Ask IRIS
How was Anondita Medicare’s balance-sheet expansion financed?
Anondita Medicare reported Rs 131.50 crore of net cash from financing activities for the half year ended September 30, 2026, compared with Rs 52.62 crore in the corresponding half year of 2025. The reported financing inflow was therefore Rs 78.88 crore higher year on year.
Long-term borrowings were Rs 42.73 crore at September 30, 2026, up from Rs 23.87 crore at March 31, 2026. Short-term borrowings increased to Rs 27.88 crore from Rs 9.73 crore over the same period. Money received against share warrants was Rs 7.40 crore at September 30, 2026, while no amount was reported under that balance-sheet line at March 31, 2026.
Share capital was Rs 19.04 crore at September 30, 2026, compared with Rs 18.09 crore at March 31, 2026, and reserves and surplus rose to Rs 221.02 crore from Rs 111.15 crore. The filing reports the borrowing, warrant and equity balances, but does not allocate particular funding sources to individual capital work-in-progress projects.
Did Anondita Medicare’s operating results also increase in the first half?
Anondita Medicare reported revenue from operations of Rs 73.54 crore for the half year ended September 30, 2026, compared with Rs 54.10 crore in the corresponding half year ended September 30, 2025. Profit before tax rose to Rs 29.45 crore from Rs 17.38 crore, while profit after tax increased to Rs 22.01 crore from Rs 13.02 crore.
Total expenses were Rs 44.69 crore in the September 2026 half year, versus Rs 37.13 crore a year earlier. Finance costs increased to Rs 4.61 crore from Rs 3.48 crore, alongside the rise in both long-term and short-term borrowings at September 30, 2026. These profit-and-loss figures are reported separately from the investing cash flow and work-in-progress balances.
The consolidated statements include Anondita Pharma and Latex Limited as a subsidiary and Anondita Healthcare as an associate. Jain Chopra & Company’s limited review report dated November 14, 2026 stated that nothing had come to its attention to indicate that the statements lacked required disclosures or contained a material misstatement. The report also stated that a review is substantially less extensive than an audit.
Conclusion
Anondita Medicare’s September 2026 consolidated statements show a substantial increase in assets under execution alongside higher revenue and profit for the half year. Capital work-in-progress reached Rs 74.21 crore and exceeded the Rs 52.97 crore balance of property, plant and equipment, while the Rs 47.94 crore investing outflow reflected continued cash deployment toward reported asset purchases and advances.
The unresolved matter is when, and into which asset categories, the Rs 74.21 crore of capital work-in-progress will be commissioned, because the filing provides neither project names nor completion schedules. Future statements can show whether work-in-progress transfers into property, plant and equipment, whether investing cash outflows continue after the Rs 62.70 crore full-year outflow in March 2026, and how borrowings develop from the September 2026 balances of Rs 42.73 crore long term and Rs 27.88 crore short term.


